A constrained funding environment and weaker Euro negatively impacted Affymetrix's gene expression array and eBioscience business units in the third quarter, causing the firm to report lower-than-expected preliminary revenues and eliciting concern from analysts and investors alike.

The Santa Clara, Calif.-based life sciences company this week said that it expects total revenue of approximately $80 million for the three months ended Sept. 30, missing an average consensus analyst expectation of $84.6 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.